Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 5/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.34 |
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | ROS1 | P08922 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362025 | 0.79 | METAP2 (0.41) | SMOTRPV1ADORA1MAPK3 | |
| SCHEMBL12629458 | 0.78 | MAPT (0.33) | GRM5TRPV1ADORA1ABL1ROS1 | |
| SCHEMBL1861926 | 0.78 | TRPV1 (0.35) | TRPV1ADORA1MAPK3 | |
| SCHEMBL1871491 | 0.75 | TRPV1 (0.62) | TRPV1MAPK3 | |
| SCHEMBL1857034 | 0.75 | TRPV1 (0.64) | TRPV1MAPK3 | |
| SCHEMBL12629465 | 0.74 | TRPV1 (0.65) | TRPV1MAPK3 | |
| SCHEMBL1860193 | 0.72 | TRPV1 (0.45) | TRPV1MAPK3 | |
| SCHEMBL4359138 | 0.71 | TRPV1 (0.43) | TRPV1MAPK3 | |
| SCHEMBL22121799 | 0.69 | MAPT (0.49) | ADORA1CYP2C9 | |
| SCHEMBL2016453 | 0.69 | ADORA1 (0.47) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1811845-A4 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1811845-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | GRM5 394/4885SMO 1598/4885TRPV1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.